Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ProCyte (US) secures marketing rights to Hymedix' Hypan

This article was originally published in Clinica

Executive Summary

ProCyte (US) has received worldwide marketing rights (outside Asia) to five of Hymedix International's Hypan polymer-based wound care products. Cleared by the US FDA, they include transparent thin film wound dressings, aquagel sheet dressings, exudate absorbers and wound moisturisers. The agreement with Hymedix (US) includes an up-front cash and common stock payment, plus future cash/royalty payments.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT094387

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel